Structures of P. falciparum Protein Kinase 7 Identify an Activation Motif and Leads for Inhibitor Design

Structure

Volumn 16, Issue 2, 2008, Pages 228-238

  Merckx, Anais ^a,b,c   Echalier, Aude ^a   Langford, Kia ^a   Sicard, Audrey ^d   Langsley, Gordon ^b,c   Joore, Jos ^e   Doerig, Christian ^d   Noble, Martin ^a   Endicott, Jane ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b INSTITUT COCHIN   (France)

^c INSERM   (France)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e Pepscan Systems   (Netherlands)

Author keywords

PROTEINS; SIGNALING

Indexed keywords

1NA PP1; 1NM PP1; 3 (4 CHLOROPHENYL) N (PYRIDIN 3 YLMETHYL)PYRAZOLOL[1,5 A]PYRIMIDIN 5 AMINE; 4 [6 (1 HYDROXY 3 METHYLBUTAN 2 YLAMINO)IMIDAZO[1,2 B]PYRIDAZIN 3 YL]BENZONITRILE; 4 [6 (TETRAHYDRO 2H PYRAN 4 YLAMINO)IMIDAZO[1,2 B]PYRIDAZIN 3 YL]BENZONITRILE; 4 AMINO 1 TERT BUTYL 3 (1' NAPHTHYL)PYRAZOLO[3,4 D]PYRIMIDINE; 4 AMINO 1 TERT BUTYL 3 (1' NAPHTHYLMETHYL)PYRAZOLO[3,4 D]PYRIMIDINE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ADENOSINE TRIPHOSPHATE; CYCLIN A; CYCLIN DEPENDENT KINASE 2; K 109; K 497; K 510; PROTEIN KINASE; PROTEIN KINASE 7; PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG STRUCTURE; HYDROGEN BOND; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE;

ADENOSINE TRIPHOSPHATE; AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; ANTIMALARIALS; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; ENZYME ACTIVATION; ENZYME INHIBITORS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PEPTIDES; PHOSPHORYLATION; PLASMODIUM FALCIPARUM; PROTEIN KINASES; PROTOZOAN PROTEINS;

EUKARYOTA; PLASMODIUM (APICOMPLEXA); PLASMODIUM FALCIPARUM;

EID: 38949134824     PISSN: 09692126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.str.2007.11.014     Document Type: Article

References (52)

1. Anamika, Srinivasan N., and Krupa A. A genomic perspective of protein kinases in Plasmodium falciparum. Proteins 58 (2005) 180-189
2. Bain J., McLauchlan H., Elliott M., and Cohen P. The specificities of protein kinase inhibitors: an update. Biochem. J. 371 (2003) 199-204
3. Birault V., Harris C.J., Le J., Lipkin M., Nerella R., and Stevens A. Bringing kinases into focus: efficient drug design through the use of chemogenomic toolkits. Curr. Med. Chem. 13 (2006) 1735-1748
4. Bishop A.C., Kung C.-y., Shah K., Witucki L., Shokat K.M., and Liu Y. Generation of monospecific nanmolar tyrosine kinase inhibitors via a chemical genetic approach. J. Am. Chem. Soc. 121 (1999) 627-631
5. Bishop A.C., Ubersax J.A., Petsch D.T., Matheos D.P., Gray N.S., Blethrow J., Shimizu E., Tsien J.Z., Schultz P.G., Rose M.D., et al. A chemical switch for inhibitor-sensitive alleles of any protein kinase. Nature 407 (2000) 395-401
6. Brown N.R., Noble M.E., Endicott J.A., and Johnson L.N. The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases. Nat. Cell Biol. 1 (1999) 438-443
7. Bullock A.N., Debreczeni J.E., Fedorov O.Y., Nelson A., Marsden B.D., and Knapp S. Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase. J. Med. Chem. 48 (2005) 7604-7614
8. Cheetham G.M., Knegtel R.M., Coll J.T., Renwick S.B., Swenson L., Weber P., Lippke J.A., and Austen D.A. Crystal structure of aurora-2, an oncogenic serine/threonine kinase. J. Biol. Chem. 277 (2002) 42419-42422
9. Chen Y., Jirage D., Caridha D., Kathcart A.K., Cortes E.A., Dennull R.A., Geyer J.A., Prigge S.T., and Waters N.C. Identification of an effector protein and gain-of-function mutants that activate Pfmrk, a malarial cyclin-dependent protein kinase. Mol. Biochem. Parasitol. 149 (2006) 48-57
10. Clamp M., Cuff J., Searle S.M., and Barton G.J. The Jalview Java alignment editor. Bioinformatics 20 (2004) 426-427
11. CCP4 (Collaborative Computational Project, Number 4). The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50 (1994) 760-763
12. Cowtan K. DM: an automated procedure for phase improvement by density modification. Joint CCP4/ESF-EACBM Newsl. Protein Crystallogr. 31 (1994) 34-38
13. Desjardins R.E., Canfield C.J., Haynes J.D., and Chulay J.D. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob. Agents Chemother. 16 (1979) 710-718
14. Doerig C., Billker O., Pratt D., and Endicott J. Protein kinases as targets for antimalarial intervention: kinomics, structure-based design, transmission-blockade, and targeting host cell enzymes. Biochim. Biophys. Acta 1754 (2005) 132-150
15. Dorin D., Le Roch K., Sallicandro P., Alano P., Parzy D., Poullet P., Meijer L., and Doerig C. Pfnek-1, a NIMA-related kinase from the human malaria parasite Plasmodium falciparum biochemical properties and possible involvement in MAPK regulation. Eur. J. Biochem. 268 (2001) 2600-2608
16. Dorin D., Semblat J.P., Poullet P., Alano P., Goldring J.P., Whittle C., Patterson S., Chakrabarti D., and Doerig C. PfPK7, an atypical MEK-related protein kinase, reflects the absence of classical three-component MAPK pathways in the human malaria parasite Plasmodium falciparum. Mol. Microbiol. 55 (2005) 184-196
17. Dorin-Semblat D., Sicard A., Doerig C., Ranford-Cartwright L., and Doerig C. Disruption of the gene encoding the atypical protein kinase PfPK7 impairs both schizogony and sporogony in Plasmodium falciparum. Eukaryot. Cell (2008) in press
18. Emsley P., and Cowtan K. Coot: model building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60 (2004) 2126-2132
19. Fischer P.M. The design of drug candidate molecules as selective inhibitors of therapeutically relevant protein kinases. Curr. Med. Chem. 11 (2004) 1563-1583
20. Hanke J.H., Gardner J.P., Dow R.L., Changelian P.S., Brissette W.H., Weringer E.J., Pollok B.A., and Connelly P.A. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J. Biol. Chem. 271 (1996) 695-701
21. Hanks S.K., and Hunter T. Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J. 9 (1995) 576-596
22. Harmse L., van Zyl R., Gray N., Schultz P., Leclerc S., Meijer L., Doerig C., and Havlik I. Structure-activity relationships and inhibitory effects of various purine derivatives on the in vitro growth of Plasmodium falciparum. Biochem. Pharmacol. 62 (2001) 341-348
23. Harris C.J., and Stevens A.P. Chemogenomics: structuring the drug discovery process to gene families. Drug Discov. Today 11 (2006) 880-888
24. Ho S.N., Hunt H.D., Horton R.M., Pullen J.K., and Pease L.R. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77 (1989) 51-59
25. Huse M., and Kuriyan J. The conformational plasticity of protein kinases. Cell 109 (2002) 275-282
26. Jones T.A., Zou J.Y., Cowan S.W., and Kjeldgaard M. Improved method for building models in electron density maps and the location of errors in these models. Acta Crystallogr. A 47 (1991) 110-119
27. Kabsch W., and Sander C. Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 22 (1983) 2577-2637
28. Knighton D.R., Zheng J.H., Ten Eyck L.F., Ashford V.A., Xuong N.H., Taylor S.S., and Sowadski J.M. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 253 (1991) 407-414
29. Knighton D.R., Zheng J.H., Ten Eyck L.F., Xuong N.H., Taylor S.S., and Sowadski J.M. Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 253 (1991) 414-420
30. Krissinel E., and Henrick K. Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. Acta Crystallogr. D Biol. Crystallogr. 60 (2004) 2256-2268
31. La Fortelle E.D., and Bricogne G. Macromolecular crystallography. In: Sweet R.M., and Carter C.W.J. (Eds). Methods in Enzymology (1997), Academic Press, New York 472-494
32. Le Roch K., Sestier C., Dorin D., Waters N., Kappes B., Chakrabarti D., Meijer L., and Doerig C. Activation of a Plasmodium falciparum cdc2-related kinase by heterologous p25 and cyclin H. Functional characterization of a P. falciparum cyclin homologue. J. Biol. Chem. 275 (2000) 8952-8958
33. Leslie A.G.W. Recent changes to the MOSFLM package for processing film and image plate data. Joint CCP4/ESF-EACBM Newsl. Protein Crystallogr. 26 (1992) 27-33
34. Li X., Lu Y., Jin W., Liang K., Mills G.B., and Fan Z. Autophosphorylation of Akt at threonine 72 and serine 246. A potential mechanism of regulation of Akt kinase activity. J. Biol. Chem. 281 (2006) 13837-13843
35. Matulis D., Kranz J.K., Salemme F.R., and Todd M.J. Thermodynamic stability of carbonic anhydrase: measurements of binding affinity and stoichiometry using ThermoFluor. Biochemistry 44 (2005) 5258-5266
36. Noble M.E., Endicott J.A., and Johnson L.N. Protein kinase inhibitors: insights into drug design from structure. Science 303 (2004) 1800-1805
37. Nwaka S., and Hudson A. Innovative lead discovery strategies for tropical diseases. Nat. Rev. Drug Discov. 5 (2006) 941-955
38. Pattanaik P., Raman J., and Balaram H. Perspectives in drug design against malaria. Curr. Top. Med. Chem. 2 (2002) 483-505
39. Peifer C., Wagner G., and Laufer S. New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase. Curr. Top. Med. Chem. 6 (2006) 113-149
40. Pizzi E., and Frontali C. Low-complexity regions in Plasmodium falciparum proteins. Genome Res. 11 (2001) 218-229
41. Renslo A.R., and McKerrow J.H. Drug discovery and development for neglected parasitic diseases. Nat. Chem. Biol. 2 (2006) 701-710
42. Ridley R.G. Introduction. Antimalarial drug resistance: ramifications, explanations and challenges. Microbes Infect. 4 (2002) 155-156
43. Sausville E.A., Elsayed Y., Monga M., and Kim G. Signal transduction-directed cancer treatments. Annu. Rev. Pharmacol. Toxicol. 43 (2003) 199-231
44. Sheldrick G. Phase annealing in SHELX-90: direct methods for larger structures. Acta Crystallogr. A 46 (1990) 467-473
45. Sweeney S.E., and Firestein G.S. Signal transduction in rheumatoid arthritis. Curr. Opin. Rheumatol. 16 (2004) 231-237
46. Thompson J.D., Higgins D.G., and Gibson T.J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22 (1994) 4673-4680
47. Tsigelny I., Greenberg J.P., Cox S., Nichols W.L., Taylor S.S., and Ten Eyck L.F. 600 ps molecular dynamics reveals stable substructures and flexible hinge points in cAMP dependent protein kinase. Biopolymers 50 (1999) 513-524
48. Ventura J.J., and Nebreda A.R. Protein kinases and phosphatases as therapeutic targets in cancer. Clin. Transl. Oncol. 8 (2006) 153-160
49. Vieth M., Higgs R.E., Robertson D.H., Shapiro M., Gragg E.A., and Hemmerle H. Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. Biochim. Biophys. Acta 1697 (2004) 243-257
50. Walliker D., Quakyi I.A., Wellems T.E., McCutchan T.F., Szarfman A., London W.T., Corcoran L.M., Burkot T.R., and Carter R. Genetic analysis of the human malaria parasite Plasmodium falciparum. Science 236 (1987) 1661-1666
51. Ward P., Equinet L., Packer J., and Doerig C. Protein kinases of the human malaria parasite Plasmodium falciparum: the kinome of a divergent eukaryote. BMC Genomics 5 (2004) 79
52. Zhou T., Raman M., Gao Y., Earnest S., Chen Z., Machius M., Cobb M.H., and Goldsmith E.J. Crystal structure of the TAO2 kinase domain: activation and specificity of a Ste20p MAP3K. Structure 12 (2004) 1891-1900